ArticleDrug safety2022
Leveraging Machine Learning to Facilitate Individual Case Causality Assessment of Adverse Drug Reactions.
Article in Drug safety, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Machine learning methods for predicting adverse drug events: A systematic review.British journal of clinical pharmacology · 2026Pooled it
- Contrastive learning of adverse events to provide effective and interpretable vector representations for machine-assisted pharmacovigilance.Briefings in bioinformatics · 2026Article
- Artificial Intelligence in Pharmacovigilance: Guiding Principles from the CIOMS Working Group XIV.Drug safety · 2026Review
- A Scoping Review of Case-Level Causality Assessment Tools Developed Between 2008 and 2023; Strengths, Weaknesses and Potential Future Improvements.Drug safety · 2026Article
- AI for Causality Assessment in Pharmacovigilance: Protocol for a Scoping Review.JMIR research protocols · 2026Article
- Beyond black boxes: using explainable causal artificial intelligence to separate signal from noise in pharmacovigilance.International journal of clinical pharmacy · 2026Article
- Artificial Intelligence for Drug Safety Across the Lifecycle and Decision Type: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- A kNN based machine learning approach to automating causality assessment of adverse events.Scientific reports · 2026Article
- How is AI developing in pharmacovigilance?Therapeutic advances in drug safety · 2026Article
- Artificial intelligence in pharmacovigilance: a narrative review and practical experience with an expert-defined Bayesian network tool.International journal of clinical pharmacy · 2025Review
- Artificial Intelligence: Applications in Pharmacovigilance Signal Management.Pharmaceutical medicine · 2025Review
- Cultural Divergence in Psychedelic Use among Medical Students: An ESPAD-Adapted Survey among Poles and Iraqis.European journal of investigation in health, psychology and education · 2024Article
- Bidirectional Encoder Representations from Transformers-like large language models in patient safety and pharmacovigilance: A comprehensive assessment of causal inference implications.Experimental biology and medicine (Maywood, N.J.) · 2023Article
- A Science-Based Methodology Framework for the Assessment of Combination Safety Risks in Clinical Trials.Pharmaceutical medicine · 2023Article
- Development and validation of a machine learning-based detection system to improve precision screening for medication errors in the neonatal intensive care unit.Frontiers in pharmacology · 2023Article
- Natural language processing for automated triage and prioritization of individual case safety reports for case-by-case assessment.Frontiers in drug safety and regulation · 2023Article
- An industry perspective on the use of machine learning in drug and vaccine safety.Frontiers in drug safety and regulation · 2023Article
- Artificial Intelligence and Machine Learning for Safe Medicines.Drug safety · 2022Article
- AI-Based Computational Methods in Early Drug Discovery and Post Market Drug Assessment: A Survey.IEEE transactions on computational biology and bioinformaticsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCausality assessment of individual case safety reports (ICSRs) is an important step in pharmacovigilance case-level review and aims to establish a position on whether a patient's exposure to a drug is causally related to the patient experiencing an untoward adverse event. There are many different approaches for case causality adjudication, including the use of expert opinions and algorithmic frameworks; however, a great deal of variability exists between assessment methods, products, therapeutic classes, individual physicians, change of process and conventions over time, and other factors.
objectiveThe objective of this study was to develop a machine learning-based model that can predict the likelihood of a causal association of an observed drug-reaction combination in an ICSR.
methodsIn this study, we used a set of annotated solicited ICSRs (50K cases) from a company post-marketing database. These data were enriched with novel supplementary features from external and internal data sources that aim to capture facets such as temporal plausibility, scientific validity, and confoundedness that have been shown to contribute to causality adjudication. Using these features, we constructed a Bayesian network (BN) model to predict drug-event pair causality assessment. BN topology was driven by an internally developed ICSR causality decision support tool. Performance of the model was evaluated through examination of sensitivity, positive predictive value (PPV), and the area under the receiver operating characteristic curve (AUC) on an independent set of data from a temporally adjacent interval (20K cases). No external validation was performed because of a lack of publicly available ICSRs with causality assessments for drug-event pairs.
resultsThe model demonstrated high performance in predicting the causality assessment of drug-event pairs compared with clinical judgment using global introspection (AUC 0.924; 95% confidence interval [CI] 0.922-0.927). The sensitivity of the model was 0.900 (95% CI 0.896-0.904), and the PPV of the model was 0.778 (95% CI 0.773-0.783).
conclusionThese results show that robust probabilistic modeling of ICSR causality is feasible, and the approach used in the development of the model can serve as a framework for such causality assessments, leading to improvements in safety decision making.
Indexed as
Identifiers
35579819What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.